ABRAXANE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Abraxane, and what generic alternatives are available?
Abraxane is a drug marketed by Bristol-myers and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and forty-two patent family members in thirty-one countries.
The generic ingredient in ABRAXANE is paclitaxel. There are sixty-nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Abraxane
A generic version of ABRAXANE was approved as paclitaxel by TEVA PHARMS on January 25th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ABRAXANE?
- What are the global sales for ABRAXANE?
- What is Average Wholesale Price for ABRAXANE?
Summary for ABRAXANE
International Patents: | 242 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 95 |
Clinical Trials: | 450 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ABRAXANE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ABRAXANE |
What excipients (inactive ingredients) are in ABRAXANE? | ABRAXANE excipients list |
DailyMed Link: | ABRAXANE at DailyMed |
![ABRAXANE drug patent expirations Drug patent expirations by year for ABRAXANE](/p/graph/s/t/ABRAXANE-patent-expirations.png)
![Drug Prices for ABRAXANE](/p/graph/drug-price/ABRAXANE.png)
Recent Clinical Trials for ABRAXANE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
280Bio Inc | Phase 1 |
Alliance for Clinical Trials in Oncology | Phase 2/Phase 3 |
Gruppo Oncologico del Nord-Ovest | Phase 2/Phase 3 |
Pharmacology for ABRAXANE
Drug Class | Microtubule Inhibitor |
Physiological Effect | Microtubule Inhibition |
Paragraph IV (Patent) Challenges for ABRAXANE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ABRAXANE | For Injection Suspension | paclitaxel | 100 mg/vial | 021660 | 1 | 2015-12-11 |
US Patents and Regulatory Information for ABRAXANE
ABRAXANE is protected by eleven US patents.
Patents protecting ABRAXANE
Combinations and modes of administration of therapeutic agents and combination therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods of delivery of pharmacological agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods of delivery of pharmacological agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combinations and modes of administration of therapeutic agents and combination therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods of delivery of pharmacological agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combinations and modes of administration of therapeutic agents and combination therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods of delivery of pharmacological agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combinations and modes of administration of therapeutic agents and combination therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating pancreatic cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ABRAXANE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ABRAXANE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Bristol-Myers Squibb Pharma EEIG | Abraxane | paclitaxel | EMEA/H/C/000778 Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. |
Authorised | no | no | no | 2008-01-11 | |
ratiopharm GmbH | Pazenir | paclitaxel | EMEA/H/C/004441 Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. |
Authorised | yes | no | no | 2019-05-06 | |
Inceptua AB | Apealea | paclitaxel | EMEA/H/C/004154 Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. |
Authorised | no | no | no | 2018-11-20 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ABRAXANE
See the table below for patents covering ABRAXANE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20050042507 | ⤷ Sign Up | |
South Korea | 20150103745 | METHODS OF TREATING PANCREATIC CANCER | ⤷ Sign Up |
Spain | 2469716 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ABRAXANE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1853250 | 2014C/037 | Belgium | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230 |
0961612 | SZ 41/2009 | Austria | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL ALBUMIN |
0961612 | 91613 | Luxembourg | ⤷ Sign Up | 91613, EXPIRES: 20220924 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |